Severe persistent visual field constriction associated with vigabatrin

Eke, Tom; Talbot, J F; Lawden, Mark

doi:10.1136/bmj.314.7075.180

Cited by 418 publications

(225 citation statements)

References 2 publications

Supporting

Mentioning

220

Contrasting

Unclassified

Order By: Relevance

“…As shown above, results reported are not always unanimous. Interestingly, no abnormalities were found during electrophysiological testing of the three patients reported by Eke et al (1997), all of whom had visual complaints due to extensive VFL, (Harding 1998).…”

Section: Discussionmentioning

confidence: 99%

Vigabatrin: longterm follow‐up of electrophysiology and visual field examinations

Hardus¹,

Verduin

Berendschot

et al. 2003

Acta Ophthalmologica Scandinavica

View full text Add to dashboard Cite

ABSTRACT.Background: To report the results of repeated electrophysiological and visual field examinations in patients with vigabatrin-associated visual field loss (VGB-VFL) and the relationship between these electrophysiological findings, the cumulative dose of vigabatrin and the extent of visual field loss. Methods: Twenty-two eyes of 11 patients with VGB-VFL were studied. All patients underwent surgery for therapy-resistant epilepsy. Repeated electrooculograms (EOGs) and flash electroretinograms (ERGs) were made and the cumulative dose of vigabatrin and the visual field loss were recorded after a period of 37-47 months. Results: The visual field loss was stable in patients who had stopped vigabatrin at the time of the first examination. There was a slight increase in VFL in patients who continued vigabatrin. During the second EOG and ERG, abnormalities in scotopic and photopic a-wave latencies and in scotopic b-wave amplitude were found in more than 50% of patients. Only b-wave latency became normal, while EOG, a-wave latency, a-wave amplitude and b-wave amplitude stayed abnormal. The amount of VFL and the cumulative dose of vigabatrin were statistically correlated with the b-wave amplitude, mainly photopic, found during the first and second examinations. Conclusion: After 4 years, EOG, flash ERG and visual field loss had not improved in patients with VGB-VFL. The statistically significant correlation found during the first examination between the amount of VFL and the cumulative dose of vigabatrin with the (mainly photopic) b-wave amplitude remained constant.

show abstract

Section: Discussionmentioning

confidence: 99%

Vigabatrin: longterm follow‐up of electrophysiology and visual field examinations

Hardus¹,

Verduin

Berendschot

et al. 2003

Acta Ophthalmologica Scandinavica

View full text Add to dashboard Cite

show abstract

“…These include tiagabine (Kaufman et al, 2001), progabide (Nordmann et al, 1999;not FDAapproved), and topiramate (Foroozan and Buono, 2003). GVG has been in use around the world for more than a decade with ϳ250,000 treated patients, mostly children, before the first report of a VFD (Eke et al, 1997). Since then, a series of studies (Nicolson et al, 2002;Schmitz et al, 2002;Bruni et al, 2000) suggests that the prevalence of concentric VFDs is on the order of 30 -50% in patients under long-term treatment whose lifetime burden exceeds 1,500 g (Manuchehri et al, 2000).…”

Section: Completersmentioning

confidence: 99%

Treating cocaine addiction: From preclinical to clinical trial experience with γ‐vinyl GABA

Brodie

Figueroa²,

Dewey

2003

Synapse

View full text Add to dashboard Cite

“…The first reports of vigabatrin-associated field loss were published in 1997 4 and since then numerous reports have been published leaving no doubt as to the validity of this relationship, with bilateral field defects generally developing in 40-45% of patients. [5][6][7] The typical visual field loss is unusual in that it is one of the few causes of bilateral nasal field loss with temporal sparing.…”

Section: Introductionmentioning

confidence: 99%

Retinal nerve fibre layer characteristics with vigabatrin-associated visual field loss—could scanning laser polarimetry aid diagnosis?

Durnian

Clearkin

2007

Eye

View full text Add to dashboard Cite

Purpose To describe the retinal nerve fibre layer (RNFL) characteristics in patients suffering vigabatrin-associated visual field loss or behaviour consistent with field loss. Methods Eight patients with visual field loss attributed to vigabatrin use had their RNFL evaluated by scanning laser polarimetry. Results All eight patients managed to perform the test reliably. The mean length of vigabatrin treatment was 81 months with a mean cumulative dose of vigabatrin being 5.4 kg. All patients had significantly reduced RNFL parameters; mean TSNIT ¼ 36.5 lm, mean nerve fibre indicator ¼ 63.1, mean superior average ¼ 42.7 lm, and mean inferior average ¼ 39.2 lm. There was no correlation between cumulative dose or time on treatment and RNFL thickness. Conclusion Scanning laser polarimetry can be performed safely and reliably on patients with vigabatrin-associated field loss. RNFL thickness is reduced in these patients with vigabatrin-associated field loss. RNFL loss concentrates on the long nerve fibres, which explains the nasal pattern of field loss seen in these patients. This investigation shows promise in the screening of vigabatrin patients, especially in those patients that may not tolerate formal field testing well.

show abstract

Severe persistent visual field constriction associated with vigabatrin

Cited by 418 publications

References 2 publications

Vigabatrin: longterm follow‐up of electrophysiology and visual field examinations

Vigabatrin: longterm follow‐up of electrophysiology and visual field examinations

Treating cocaine addiction: From preclinical to clinical trial experience with γ‐vinyl GABA

Retinal nerve fibre layer characteristics with vigabatrin-associated visual field loss—could scanning laser polarimetry aid diagnosis?

Contact Info

Product

Resources

About